Project Grant R01HL189487
Award Date 8/15/26
Completion Date 5/31/31
Dollars Obligated $837K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Roxbury, MA 02118, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Beth Israel Deaconess Medical Center, Inc. $1,725,948 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to generate real-world evidence on the effectiveness, safety, and value of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for cardiovascular disease prevention among individuals with cardiovascular-kidney-metabolic syndrome. The project addresses a critical evidence gap: while randomized controlled...
- The National Heart, Lung, and Blood Institute awarded Beth Israel Deaconess Medical Center, Inc. $169,504 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize treatment gaps in GLP-1 receptor agonist access for low-income, working-age adults with obesity and evaluate the impact of state Medicaid policy expansions on cardiovascular health outcomes in this population. The project, designated K23HL183890, runs through May 31, 2031, with performance at...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $1,282,827 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a multicenter randomized placebo-controlled trial evaluating glucagon-like peptide-1 receptor agonist therapy on inflammation and atherosclerosis in persons living with HIV. The study will enroll 125 treatment-suppressed participants aged 40 and older with known cardiovascular disease or at least...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Harvard T.H. Chan School of Public Health $456,000 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to elucidate novel metabolic actions of glucagon-like peptide-1 (GLP-1) receptor agonists. The research investigates regulatory and metabolic pathways through which GLP-1 receptor agonists such as liraglutide and semaglutide exert effects beyond their known...
- The National Heart, Lung, and Blood Institute awarded the University of Texas Health Science Center at Houston $255,458 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct the Preparing for Semaglutide Microdosing to Maintain Cardiovascular Health in People with HIV (PRE-SMASH CVD) trial, a pilot study designed to determine preliminary effects of semaglutide microdosing in maintaining weight and cardiometabolic health in people with HIV following...
- The National Heart, Lung, and Blood Institute awarded the Trustees of Boston University $849,790 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to decode regulatory variants in cardiovascular disease through functional annotation of non-coding variants associated with CVD. The recipient will characterize non-coding regulatory variants and their mechanisms using high-throughput experimental approaches in human cardiomyocytes. Aim 1 encompasses biophysical...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $1,634,996 to Boston University (Trustees of Boston University, doing business as Boston University Medical Campus) on February 18, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to support research on vasculature and beige remodeling of obese adipose tissue. The research investigates how beige adipocyte recruitment and enhanced angiogenesis can counteract unhealthy...
- The National Heart, Lung, and Blood Institute awarded Northwestern University $1,477,950 on September 10, 2025, under CFDA 93.837 (Cardiovascular Diseases Research) to conduct observational research defining the optimal interval for women to delay pregnancy after discontinuing long-acting glucagon-like peptide-1 receptor agonists (GLP-1 RAs). The research addresses evidence gaps in pregnancy and postpartum outcomes following GLP-1 RA discontinuation. GLP-1 RAs, now established therapies for...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $835,245 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds research to evaluate evidence-based strategies for preventing weight regain after discontinuation of high-dose glucagon-like peptide-1 (GLP-1) agonist therapy in adults with obesity history but...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Texas Health Science Center at Houston $1.933 million on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) for a clinical trial examining semaglutide microdosing in people living with HIV. The REINFORCE Trial investigates whether low-dose (0.5 milligram weekly) semaglutide maintenance therapy sustains weight loss and cardiometabolic...